Skip to content

Study · Randomized controlled trial · n = 91 · 2016

3 results

No benefit of additional treatment with exenatide in patients with an acute myocardial infarction.

Roos ST, Timmers L, Biesbroek PS, Nijveldt R, Kamp O, van Rossum AC, van Hout GP, Stella PR, Doevendans PA, Knaapen P, Velthuis BK, van Royen N, Voskuil M, Nap A, Appelman Y

International journal of cardiology29 Jun 2016Cited by 40 (Europe PMC)

PMID27394978 (opens in a new tab)DOI10.1016/j.ijcard.2016.06.283 (opens in a new tab)PepBankPUB-27394978
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

ObjectivesThis double blinded, placebo controlled randomized clinical trial studies the effect of exenatide on myocardial infarct size. The glucagon-like peptide-1 receptor agonist exenatide has possible cardioprotective properties during reperfusion after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Methods191 patients were randomly assigned to intravenous exenatide or placebo initiated prior to percutaneous coronary intervention using 10μg/h for 30min followed by 0.84μg/h for 72h. Patients with a previous myocardial infarction, Trombolysis in Myocardial Infarction flow 2 or 3, multi-vessel disease, or diabetes were excluded. Magnetic resonance imaging (MRI) was performed to determine infarct size, area at risk (AAR) (using T2-weighted hyperintensity (T2W) and late enhancement endocardial surface area (ESA)). The primary endpoint was of 4-month final infarct size, corrected for the AAR measured in the acute phase using MRI.ResultsAfter exclusion, 91 patients (age 57.4±10.1years, 76% male) completed the protocol. There were no baseline differences between groups. No difference was found in infarct size corrected for the AAR in the exenatide group compared to the placebo group (37.1±18.8 vs. 39.3±20.1%, p=0.662). There was also no difference in infarct size (18.8±13.2 vs. 18.8±11.3% of left ventricular mass, p=0.965). No major adverse cardiac events occurred during the in-hospital phase.ConclusionExenatide did not reduce myocardial infarct size expressed as a percentage of AAR in ST elevated myocardial infarction patients successfully treated with percutaneous coronary intervention.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In myocardial infarction patients, exenatide did not significantly change infarct size corrected for area at risk versus placebo.

    In plain wordsIn heart attack patients, exenatide did not significantly change infarct size relative to the area at risk compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInfarct size corrected for area at risk
    Study

    n = 91

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 μg/h for 30 min, then 0.84 μg/h for 72 h · intravenous · 72 hAs given in this study (human).

    Measurements

    Corrected infarct size
    37.1%
    exenatide
    Corrected infarct size
    39.3%
    placebo

    Source sentences

    Summary
    No difference was found in infarct size corrected for the AAR in the exenatide group compared to the placebo group (37.1±18.8 vs. 39.3±20.1%, p=0.662).
    1 context sentence
    Summary · context
    191 patients were randomly assigned to intravenous exenatide or placebo initiated prior to percutaneous coronary intervention using 10μg/h for 30min followed by 0.84μg/h for 72h.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In myocardial infarction patients, exenatide did not significantly change infarct size as a percentage of left ventricular mass versus placebo.

    In plain wordsIn heart attack patients, exenatide did not significantly change infarct size as a share of heart muscle compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInfarct size as percentage of left ventricular mass
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 μg/h for 30 min, then 0.84 μg/h for 72 h · intravenous · 72 hAs given in this study (human).

    Measurements

    Infarct size
    18.8 % of left ventricular mass
    exenatide
    Infarct size
    18.8 % of left ventricular mass
    placebo

    Source sentences

    Summary
    There was also no difference in infarct size (18.8±13.2 vs. 18.8±11.3% of left ventricular mass, p=0.965).
    1 context sentence
    Summary · context
    191 patients were randomly assigned to intravenous exenatide or placebo initiated prior to percutaneous coronary intervention using 10μg/h for 30min followed by 0.84μg/h for 72h.
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with ST-elevation myocardial infarction randomised to exenatide or placebo, no major adverse cardiac events occurred in hospital.

    In plain wordsIn heart attack patients given exenatide or placebo, no major heart complications occurred in hospital.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIn-hospital major adverse cardiac events
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 μg/h for 30 min, then 0.84 μg/h for 72 h · intravenous · 72 hAs given in this study (human).

    Source sentences

    Summary
    No major adverse cardiac events occurred during the in-hospital phase.
    1 context sentence
    Summary · context
    191 patients were randomly assigned to intravenous exenatide or placebo initiated prior to percutaneous coronary intervention using 10μg/h for 30min followed by 0.84μg/h for 72h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.